05 April 2012

GEA Lyophil GmbH, part of GEA Pharma Systems and one of the market leaders in freeze drying / lyophilization technology, has signed a license agreement to use Praxair’s ControLyo™ nucleation on-demand technology. ControlLyo™ controls the freezing step of lyophilization by controlling the nucleation temperature to within 1°C of its freezing point. The results are improved product uniformity, quality, yield and a reduction in cycle time by as much as 40%.

The agreement is an obvious fit between the two companies: GEA Lyophil being the market leader in pharmaceutical freeze drying; Praxair, the largest industrial gases company in America producing atmospheric, process and specialty gases, and high-performance surface coatings.

“The integration of Praxair´s ControLyo™ technology into our laboratory and production scale freeze dryers is another important step in our approach to provide comprehensive lyophization to our clients that combines predictable and reproducible product quality with the best drying performance,” said Heinrich Meintrup, Managing Director of GEA Lyophil.

“The addition of Praxair’s ControLyo™ nucleation on-demand technology to GEA Lyophil´s freeze-dryers provides drug manufacturers with precise control of the lyophilization process using one of the most advanced and innovative freeze-drying tools on the market today,” said Rich Jarrett, Global Director of Marketing and Business Development for Praxair’s Biopharma business.

GEA Lyophil has more than 55 years’ experience and a reference record of over 1,000 freeze dryer installations worldwide. The company is certified to ISO 9001 and performs in full compliance with the cGMP, GAMP and other relevant guidelines.


All editorial enquiries to:
Steve Jordan - The Words Workshop
Tel: +44 1908 695500

For further business information contact:
Hubert Kluetsch - Director Sales and Marketing
GEA Lyophil GmbH
Kalscheurener Str. 92 50354 Huerth Germany
Tel: +49 (0) 2233/6999-220 Fax: +49 (0) 2233/6999-8220